Save time and get answers to complex questions with AI chat
Pramlintide fda approval date?Are there income restrictions for lipitor's patient program?What are the most memorable drug brands in oral factor b inhibitors? in united statesNorcuron generic name?How many years does kadcyla's market exclusivity last?
See the DrugPatentWatch profile for spravato
What to Expect from a Spravato Session A typical Spravato session involves administering the drug through an intranasal spray. The dosage varies depending on the medical condition being treated and the specific protocol. Standard Spravato Dose According to the Food and Drug Administration (FDA) approval, the standard dose for Spravato (esketamine) is administered intranasally, with two 28mg doses, separated by at least 2 hours. This is typically done in an outpatient setting under the supervision of a certified healthcare provider [1]. Dosing Frequency In clinical trials, Spravato was evaluated for its efficacy in treating major depressive disorder (MDD) in adult patients who have not responded to other treatments [2]. The dosing regimen in these studies included two intranasal doses of 56 mg (28 mg per nostril) on the first and second days of each treatment cycle, administered in the morning, followed by two doses of 28 mg on subsequent treatment days. This dosing schedule was repeated every 3 days, for 4-8 cycles. However, the specific dosing frequency and regimen may vary depending on the patient's response and healthcare provider's discretion. Monitoring and Supervision It is essential to note that Spravato must be administered under the supervision of a certified healthcare provider, and patients are required to stay in the office or healthcare setting for at least 2 hours after the administration. This allows for monitoring of potential side effects and any necessary interventions [3]. References: [1] FDA. (2020, December 23). Spravato. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safe ty-upDATES/spravato-esketamine-cassa-cassava-cassettes [2] FDA. (2019, March 5). FDA Approves NDA for esketamine (Spravato) for Treatment of Treatment-Resistant Depression. Retrieved from https://www.fda.gov/drugs/fda-expands-spravato- esketamine-cassette-s-treatment-of-depression [3] Janssen Pharmaceuticals. (n.d.). SPRAVATO (esketamine) CIII Nasal Spray. Retrieved from https://www.janssen.com/us/en/products/spravato
Other Questions About Spravato :